These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30350109)

  • 1. Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.
    Nakano Y; Tomiyama A; Kohno T; Yoshida A; Yamasaki K; Ozawa T; Fukuoka K; Fukushima H; Inoue T; Hara J; Sakamoto H; Ichimura K
    Brain Tumor Pathol; 2019 Jan; 36(1):14-19. PubMed ID: 30350109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
    Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
    Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor.
    Kiehna EN; Arnush MR; Tamrazi B; Cotter JA; Hawes D; Robison NJ; Fong CY; Estrine DB; Han JH; Biegel JA
    J Neurosurg Pediatr; 2017 Jul; 20(1):51-55. PubMed ID: 28387643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors.
    Richardson TE; Tang K; Vasudevaraja V; Serrano J; William CM; Mirchia K; Pierson CR; Leonard JR; AbdelBaki MS; Schieffer KM; Cottrell CE; Tovar-Spinoza Z; Comito MA; Boué DR; Jour G; Snuderl M
    J Neuropathol Exp Neurol; 2019 Dec; 78(12):1089-1099. PubMed ID: 31626289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of ROS1 rearrangement in gastric adenocarcinoma.
    Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
    Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma.
    Houang M; Toon CW; Clarkson A; Sioson L; de Silva K; Watson N; Singh NR; Chou A; Gill AJ
    Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):134-8. PubMed ID: 24992173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.
    Zhu YC; Zhou YF; Wang WX; Xu CW; Zhuang W; Du KQ; Chen G
    Thorac Cancer; 2018 May; 9(5):652-655. PubMed ID: 29517860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
    Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
    Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.
    Hornick JL; Sholl LM; Dal Cin P; Childress MA; Lovly CM
    Mod Pathol; 2015 May; 28(5):732-9. PubMed ID: 25612511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel
    Deland L; Keane S; Bontell TO; Fagman H; Sjögren H; Lind AE; Carén H; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
    Cancer Genomics Proteomics; 2022; 19(6):711-726. PubMed ID: 36316040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
    Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
    Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.